Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase
Keywords: نئوپلاسم میلوپرولیفراتیو; Myeloproliferative neoplasm; AML; Accelerated phase; Myelofibrosis; Decitabine;